Myriad Genetics (NASDAQ:MYGN) Releases Earnings Results, Beats Expectations By $0.03 EPS

Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03, Briefing.com reports. The business had revenue of $196.60 million for the quarter, compared to analysts’ expectations of $194.80 million. Myriad Genetics had […]

Related Keywords

Canada ,Hong Kong ,United States ,Piper Sandler ,Wolfe Research ,Tower Research Capital ,Wells Fargo Company ,Us Bancorp ,Jpmorgan Chase Co ,Royal Bank ,Goldman Sachs Group ,Genetics Company Profile ,Hong Kong Ltd ,Genetics Inc ,Myriad Genetics ,Get Free Report ,Research Capital ,Kong Ltd ,Myrisk Hereditary Cancer Test ,Germline Companion Diagnostic Test ,Companion Diagnostic Test ,Myriad Genetics Daily ,Nasdaq Mygn ,Mygn ,Medical ,62855j10 ,Earnings ,